GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Subscribe To Our Newsletter & Stay Updated